Status:

COMPLETED

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Lead Sponsor:

Medical Research Council

Conditions:

Malignant Mesothelioma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

RATIONALE: Active symptom control may decrease chest pain, breathlessness, sweating, and general discomfort in patients with malignant pleural mesothelioma. It is not yet known if active symptom contr...

Detailed Description

OBJECTIVES: Primary * Compare the overall survival of patients with malignant pleural mesothelioma treated with active symptom control (ASC) alone vs ASC and mitomycin, vinblastine, and cisplatin vs...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically and immunohistochemically confirmed malignant pleural mesothelioma
  • Epithelial and other histological types are allowed
  • No more than 3 months since diagnosis
  • Symptomatic pleural effusion must have been treated and brought under control by drainage, pleurodesis, or pleurectomy
  • Prior surgical resection of mesothelioma allowed provided 2 CT scans at least 6 weeks apart show stable or progressive disease
  • PATIENT CHARACTERISTICS:
  • Age
  • 18 and over
  • Performance status
  • WHO 0-2
  • Life expectancy
  • Not specified
  • Hematopoietic
  • WBC \> 3,000/mm\^3
  • Absolute neutrophil count \> 1,500/mm\^3
  • Platelet count \> 100,000/mm\^3
  • Hepatic
  • Not specified
  • Renal
  • Creatinine clearance \> 50 mL/min
  • Pulmonary
  • See Disease Characteristics
  • Other
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Considered medically fit to receive chemotherapy
  • No other disease or prior malignancy likely to interfere with protocol treatments or comparisons
  • No clinical evidence of infection
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • No prior chemotherapy for mesothelioma
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • Prior local radiotherapy to a wound site after exploratory thoracotomy allowed
  • Surgery
  • See Disease Characteristics
  • See Radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    September 1 2003

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    840 Patients enrolled

    Trial Details

    Trial ID

    NCT00075699

    Start Date

    September 1 2003

    Last Update

    August 7 2013

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Leeds General Infirmary at Leeds Teaching Hospital NHS Trust

    Leeds, England, United Kingdom, LS1 3EX

    2

    Saint Bartholomew's Hospital

    London, England, United Kingdom, EC1A 7BE

    3

    Royal Marsden NHS Foundation Trust - Surrey

    Sutton, England, United Kingdom, SM2 5PT